Sodium, Potassium- Blood Pressure, Mortality, and Cardiovascular Events

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1304127

Lot of statistical language but guess we can agree on the results

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1311989
http://www.nejm.org/doi/pdf/10.1056/NEJMoa1311889

Interesting findings. 

Does it change anything in clinical practice?

PKD & Ca after transplant

http://jasn.asnjournals.org/content/25/10/2335.full.pdf

Interesting findings, especially RCC ( possible reason in discussion section) 

Nephrology- NEJM recently

Hyperkalemia treatment
http://www.nejm.org/doi/pdf/10.1056/NEJMoa1411487
http://www.nejm.org/doi/pdf/10.1056/NEJMoa1410853
http://www.nejm.org/doi/pdf/10.1056/NEJMe1414112

HALT-PKD
http://www.nejm.org/doi/pdf/10.1056/NEJMoa1402685
http://www.nejm.org/doi/pdf/10.1056/NEJMoa1402686
http://www.nejm.org/doi/pdf/10.1056/NEJMe1412586

Very Interesting

http://renalfellow.blogspot.com/2014/11/creatininase.html

Aldactone and Heart failure with preserved EF

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1313731

ACEI and first trimester

http://www.nejm.org/doi/pdf/10.1056/NEJMoa055202
http://www.bmj.com/content/343/bmj.d5931.pdf%2Bhtml
http://www.cfp.ca/content/53/9/1439.full.pdf

End of supar and fsgs story?

Seems like that.. three studies ( from Europe, Japan and India) published in Jan issue of KI.. one issue three hits!!
http://www.nature.com/ki/journal/v85/n3/pdf/ki2013505a.pdf
http://www.nature.com/ki/journal/v85/n3/pdf/ki2013544a.pdf
http://www.nature.com/ki/journal/v85/n3/pdf/ki2013546a.pdf

Twenty five year follow-up for breast cancer incidence and mortality

No Nephrology here but,  its all over the news so...

http://www.bmj.com/content/348/bmj.g366

Interesting responses/critic and at times dismissal of the trial results:
http://www.bmj.com/content/348/bmj.g366?tab=responses

Risk of End-Stage Renal Disease Following Live Kidney Donation

http://jama.jamanetwork.com/article.aspx?articleid=1829682

Median follow-up of 7.6 years (maximum, 15.0)

Estimated risk of ESRD at 15 years after donation was 30.8 per 10 000 (95% CI, 24.3-38.5) in kidney donors and 3.9 per 10 000 (95% CI, 0.8-8.9) in their matched healthy nondonor counterparts (P < .001). 

Estimated risk of 74.7 per 10 000 black donors (95% CI, 47.8-105.8) vs 23.9 per 10 000 black nondonors (95% CI, 1.6-62.4; P < .001) 

Estimated risk of 22.7 per 10 000 white donors (95% CI, 15.6-30.1) vs 0.0 white nondonors (P < .001).

 Estimated lifetime risk of ESRD was 90 per 10 000 donors, 326 per 10 000 unscreened nondonors (general population), and 14 per 10 000 healthy nondonors.

Conclusions: Compared with matched healthy nondonors, kidney donors had an increased risk of ESRD over a median of 7.6 years; however, the magnitude of the absolute risk increase was small. 

Thromboprophylaxis in ESRD- UFH vs LMWH

http://www.nature.com/ki/journal/v84/n3/pdf/ki2013152a.pdf

atenolol or lisinopril in hypertensive HD patients

http://www.ncbi.nlm.nih.gov/pubmed/24398888

SYMPLICITY HTN 3 press release

http://newsroom.medtronic.com/phoenix.zhtml?c=251324&p=irol-newsArticle&ID=1889335&highlight=&utm_source=MDT_com_Symplifybptrial_Home_Page&utm_medium=Impt_Info_ReadPR_Link&utm_campaign=Renal_Denervation_RDN_Press_Release_010914

ESRD and anticoagulation

http://circ.ahajournals.org/content/early/2014/01/22/CIRCULATIONAHA.113.004777.abstract

Also, nice mini review article in last month JASN about evidence based cardiology in ESRD patients which has section on anticoagulation too. 

APOL1 Risk Variants, Race, and Progression of Chronic Kidney Disease — NEJM

APOL1 Risk Variants, Race, and Progression of Chronic Kidney Disease — NEJM

Renal Fellow Network: Cholesterol Management.

Renal Fellow Network: Cholesterol Management.: Cholesterol management, what to do? New guidelines on managing cholesterol were published in Circulation this month by the ACC/AHA tas...

Nephron Power: Crizotinib and the Kidney

Nephron Power: Crizotinib and the Kidney

Time to stop ordering Urine Eos?

Urinary eosinophils don't add much information to either exclude or confirm a diagnosis of AIN:
http://cjasn.asnjournals.org/content/8/11/1857.abstract

Nephron Power: The MORAL of CORAL

Nephron Power: The MORAL of CORAL

Renal Fellow Network: Abatacept for Glomerular Diseases: A New Era of In...

Renal Fellow Network: Abatacept for Glomerular Diseases: A New Era of In...: At ASN Kidney Week there was some interest in abatacept as a targeted therapy for glomerular diseases. T-cell activation requires 2 signa...

VA NEPHRON-D study

Another nail in the coffin for combination ACE/ARB in diabetic nephropathy!
http://www.nejm.org/doi/full/10.1056/NEJMoa1303154?query=TOC

Also see Kiran/Pradeep's posts on this article on Nov 10th.
Regarding Pradeep's question: might there still be a role for combined ACE/ARB in non-diabetics with CKD and proteinuria?  Obviously this study was in diabetics and will not directly inform ACE+ARB use in non-diabetics. But its impressive that their findings generally confirm those in ONTARGET, suggesting adverse outcomes (renal failure, hyperkalemia) with combination therapy.  ONTARGET included both diabetics and non-diabetics, and subgroup analysis suggested the adverse outcomes were not affected by the presence/absence of diabetes.

So I will continue to consider combined ACE/ARB only in very exceptional circumstances (perhaps multi-drug resistant hypertension and/or severe refractory proteinuria), and only with diligent laboratory monitoring.